Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
A Phase 2 Randomized Study Comparing Radium Ra 223 Dichloride Plus Enzalutamide With Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer
Sponsor: University of Utah
Listed as NCT02199197, this PHASE2 trial focuses on Prostate Cancer and remains completed. Sponsored by University of Utah, it has been updated 13 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Nov 2019 — Nov 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jun 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — May 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Jun 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Utah
For direct contact, visit the study record on ClinicalTrials.gov .